Literature DB >> 31036976

Biosimilar Drugs and the Hospital Formulary: A Canadian Experience.

Jennifer Fenna1, Kathy Watkins2, Micheal Guirguis3.   

Abstract

Year:  2018        PMID: 31036976      PMCID: PMC6476576     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


× No keyword cloud information.
  3 in total

Review 1.  Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes.

Authors:  Alireza Lashay; Hooshang Faghihi; Ahmad Mirshahi; Hassan Khojasteh; Alireza Khodabande; Hamid Riazi-Esfahani; Fahimeh Asadi Amoli; Elias Khalili Pour; Elham Delrish
Journal:  J Ophthalmic Vis Res       Date:  2020-08-06

2.  Effect on Patients' Outcomes of a Change to Biosimilar Filgrastim Product in Autologous Stem Cell Mobilization.

Authors:  Jennifer Fenna; Micheal Guirguis; Caroline Ibrahim; Neeta Shirvaikar; Irwindeep Sandhu; Sunita Ghosh; Melissa Jenkins
Journal:  Can J Hosp Pharm       Date:  2021-04-01

3.  Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes.

Authors:  Alireza Lashay; Hamid Riazi-Esfahani; Hooshang Faghihi; Ahmad Mirshahi; Hassan Khojasteh; Alireza Khodabande; Fahimeh Asadi Amoli; Fariba Ghassemi; Fatemeh Bazvand; Elias Khalili Pour; Nazanin Ebrahimiadib; Ali Torkashvand; Elham Delrish
Journal:  J Ophthalmol       Date:  2020-07-03       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.